Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma

Adoptive T-cell therapy (ACT) is a highly intensive immunotherapy regime that has yielded remarkable response rates and many durable responses in clinical trials in melanoma; however, 50–60% of the patients have no clinical benefit. Here, we searched for predictive biomarkers to ACT in melanoma. Who...

Descripción completa

Detalles Bibliográficos
Autores principales: Lauss, Martin, Donia, Marco, Harbst, Katja, Andersen, Rikke, Mitra, Shamik, Rosengren, Frida, Salim, Maryem, Vallon-Christersson, Johan, Törngren, Therese, Kvist, Anders, Ringnér, Markus, Svane, Inge Marie, Jönsson, Göran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701046/
https://www.ncbi.nlm.nih.gov/pubmed/29170503
http://dx.doi.org/10.1038/s41467-017-01460-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701046/
https://www.ncbi.nlm.nih.gov/pubmed/29170503
http://dx.doi.org/10.1038/s41467-017-01460-0

Ejemplares similares